In conclusion, we determined various roles for PRMT5 in BLV infection in vivo and in vitro; CMP5 and other PRMT5 inhibitors should be further investigated and evaluated in clinical studies as a novel antiretroviral therapy. This evidence concerns the gene PRMT5 and deltaretrovirus infections.